Coping with small populations of patients in clinical trials

Expert Opinion on Orphan Drugs

Volumn 2, Issue 8, 2014, Pages 765-768

  O'Connor, Daniel J ^a   Hemmings, Robert James ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Clinical trials; Small populations; Study design

Indexed keywords

CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COPING BEHAVIOR; EUROPEAN UNION; HUMAN; LICENSING; PATIENT ADVOCACY; PATIENT EDUCATION; POPULATION; PRIORITY JOURNAL; REVIEW;

EID: 84904988111     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.931221     Document Type: Review

References (15)

1. European Medicines Agency. 2006. Committee for medicinal products for human use. Guideline on clinical trials in small populations. Doc. Ref. CHMP/EWP/83561/2005
2. Buckley BM. Clinical trials of orphan medicines. Lancet 2008;371:2051-5
3. Cornu C, Kassai B, Fisch R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis 2013;8:48
4. Griggs RC, Batshaw M, Dunkle M. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009;96(1):20-6
5. Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. 2013.5(178): 178sr3. Available from: www.ScienceTranslationalMedicine.org [Last accessed 2nd June 2014]
6. Hemmings RJ, Lewis JA. The implications of current methodological issues for international guidance. Stat Biopharm Res 2013;5(3):211-22
7. European Medicines Agency. 2007. Committee for medicinal products for human use. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. Doc. Ref. CHMP/EWP/2459/02
8. Berry DA. Statistics: a bayesian perspective. Duxbury; London: 1996
9. Hannemann-Weber H, Kessel M, Schultz C. Research performance of centers of expertise for rare diseases-The influence of network integration, internal resource access and operational experience. Health Policy 2012;105(2-3):138-45
10. European Medicines Agency. Committee for medicinal products for human use. Guideline on Missing Data in Confirmatory Clinical Trials. EMA/CPMP/EWP/1776/99 Rev. 1. 2010
11. MHRA innovation office. Available from: http://www.mhra.gov.uk/ Howweregulate/Innovation/index.htm [Last accessed 2nd June 2014]
12. European Medicines Agency. Committee for medicinal products for human use. Points to consider on applications with 1.Meta-analysis; 2. One pivotal study CPMP/EWP/2330/99. 2010
13. EMA Adaptive licencing pilot. Available from: http://www.ema.europa.eu/ ema/index.jsp?curl=pages/news-and-events/news/2014/03/news-detail-002046. jsp&mid=WC0b01ac058004d5c1 [Last accessed 2nd June 2014]
14. European Commission. Research & Innovation in Health-Rare Diseases page. Available from: http://ec.europa.eu/research/health/medical-research/rare- diseases/index-en.html [Last accessed 2nd June 2014]
15. European Commission. Clinical Added Value of Orphan Drugs (CAVOD). 2011. Available from: http://ec.europa.eu/eahc/news/news96.html [Last accessed 2nd June 2014]